Phaseline

Companies › Aurigene Discovery Technologies

Aurigene Discovery Technologies: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AUR107
AURKA inhibitor
–Phase 1Relapsed Malignant Solid NeoplasmJan 2027
AUR112–Phase 1Relapsed Advanced LymphomasJan 2027
AUR108
HDM2 inhibitor
–Phase 1Relapsed Advanced LymphomasAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05865002AUR107Phase 1Relapsed Malignant Solid NeoplasmOncologyJan 2027
NCT06755450AUR112Phase 1Relapsed Advanced LymphomasOncologyJan 2027
NCT05984147AUR108Phase 1Relapsed Advanced LymphomasOncologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.